![conference banner](/images/conference-banner.jpeg)
摘要
在过去的三十年里广泛的研究已经表明,代谢型谷氨酸(mGlu)受体在中枢神经系统(CNS)主要功能中有重要作用。很多的临床前研究提供的证据表明,代谢型谷氨酸受体的靶向药物能有效减轻动物模型中的症状发展和许多中枢神经系统疾病的进展。本综述总结了在病理生理学神经精神疾病(精神分裂症、抑郁症、焦虑症和认知障碍,疼痛的感知和上瘾)参与代谢型谷氨酸受体的当前知识,包括神经退行性疾病(老年痴呆症,阿尔茨海默氏病和帕金森病)和神经发育(脆性X综合症和自闭症谱系障碍)疾病。我们进一步强调治疗在这些疾病中代谢型谷氨酸受体的药理调节潜力,用这些化合物描述临床试验的结果和讨论转化困难的潜在来源。
关键词: 自闭症,脆性X综合症,精神障碍,代谢型谷氨酸受体,神经退行性疾病,疼痛。
Current Drug Targets
Title:Metabotropic Glutamate Receptors in Central Nervous System Diseases
Volume: 17 Issue: 5
Author(s): Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan
Affiliation:
关键词: 自闭症,脆性X综合症,精神障碍,代谢型谷氨酸受体,神经退行性疾病,疼痛。
摘要: Extensive research over the past thirty years has demonstrated a vital role for metabotropic glutamate (mGlu) receptors in the major functions of the central nervous system (CNS). A wealth of preclinical studies provide evidence that pharmacological targeting of mGlu receptors can effectively attenuate the development of symptoms and progression of many CNS disorders in animal models. In this review we summarize the current knowledge on the involvement of mGlu receptors in the pathophysiology of neuropsychiatric disorders (schizophrenia, depression, anxiety and cognitive disorders, pain perception and addiction), as well as neurodegenerative (Alzheimer’s, Huntington’s and Parkinson’s diseases) and neurodevelopmental (fragile X syndrome and autism spectrum disorders) diseases. We further emphasize the therapeutic potential of mGlu receptors’ pharmacological modulators in these diseases, describe the results of clinical trials with these compounds and discuss the potential sources of translational difficulties.
Export Options
About this article
Cite this article as:
Anna V. Golubeva, Rachel D. Moloney, Richard M. O’Connor, Timothy G. Dinan and John F. Cryan , Metabotropic Glutamate Receptors in Central Nervous System Diseases, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666150316224011
DOI https://dx.doi.org/10.2174/1389450116666150316224011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design PAK1 Inhibition Suppresses the Proliferation, Migration and Invasion of Glioma Cells
Current Protein & Peptide Science Metabolic and Functional Brain Mapping, Connectivity and Plasticity Applied to the Surgery of Cerebral Tumors
Current Medical Imaging Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Pharmacokinetics and Disposition of Various Drug Loaded Liposomes
Current Drug Metabolism Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials The Role of Tumor-related LncRNA PART1 in Cancer
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry DAB389EGF Fusion Protein Therapy of Refractory Glioblastoma Multiforme
Current Pharmaceutical Biotechnology Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism